{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:57:57Z","timestamp":1792292277015,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.dld.2017.05.011","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T13:33:37Z","timestamp":1495546417000},"page":"831-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0341-1812","authenticated-orcid":false,"given":"Laurence","family":"Moureau-Zabotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Goere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Siproudhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.05.011_bib0005","unstructured":"Moureau-Zabotto L, Abramowitz L, Francois E, Goere D, Huguet F, Vendrely Peiffert D, Siproudhis L, Cancer du canal anal. Th\u00e9saurus National de Canc\u00e9rologie Digestive, 10-2016, [On line] http:\/\/www.tncd.org."},{"key":"10.1016\/j.dld.2017.05.011_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2009.04026.x","article-title":"Epidermoid anal cancer prognosis comparison among HIV+ and HIV\u2212 patients","volume":"30","author":"Abramowitz","year":"2009","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"10.1016\/j.dld.2017.05.011_bib0015","unstructured":"FNCLCC. Enqu\u00eate Permanente Cancer 1976\u20131989: survie \u00e0 long terme des malades trait\u00e9s pour cancer. Monographie FNCLCC 1992."},{"key":"10.1016\/j.dld.2017.05.011_bib0020","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"Suppl. 3","key":"10.1016\/j.dld.2017.05.011_bib0025","doi-asserted-by":"crossref","first-page":"iii10","DOI":"10.1093\/annonc\/mdu159","article-title":"Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.dld.2017.05.011_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0040","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.humpath.2012.08.019","article-title":"Signature patterns of human papillomavirus type 16 in invasive anal carcinoma","volume":"44","author":"Valmary-Degano","year":"2013","journal-title":"Human Pathology"},{"key":"10.1016\/j.dld.2017.05.011_bib0045","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1200\/JCO.2012.44.5486","article-title":"Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV","volume":"30","author":"Piketty","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0050","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/jnci\/92.18.1500","article-title":"Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome","volume":"92","author":"Frisch","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.dld.2017.05.011_bib0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M","article-title":"Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases","volume":"58","author":"Penn","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0065","first-page":"194","article-title":"On the etiology of anal squamous carcinoma","volume":"49","author":"Frisch","year":"2002","journal-title":"Danish Medical Bulletin"},{"key":"10.1016\/j.dld.2017.05.011_bib0070","first-page":"145","article-title":"Tumours of the anal canal. Pathology and genetic tumors of the digestive system","volume":"2","author":"Fenger","year":"2000","journal-title":"Pathology and Genetics"},{"key":"10.1016\/j.dld.2017.05.011_bib0075","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.05.011_bib0080","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0085","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0090","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0095","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"The Lancet"},{"key":"10.1016\/j.dld.2017.05.011_bib0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2014.11.013","article-title":"Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer","volume":"113","author":"Koerber","year":"2014","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0110","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0115","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.critrevonc.2016.03.001","article-title":"Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers","volume":"101","author":"Delhorme","year":"2016","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.dld.2017.05.011_bib0125","series-title":"Anal canal. American Joint Committee on Cancer","first-page":"106","author":"AJCC","year":"2011"},{"key":"10.1016\/j.dld.2017.05.011_bib0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1259\/bjr\/96187638","article-title":"Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation","volume":"81","author":"Koh","year":"2008","journal-title":"British Journal of Radiology"},{"key":"10.1016\/j.dld.2017.05.011_bib0135","unstructured":"National Comprehensive Cancer Network (NCCN). Guidelines for Anal Carcinoma. Fort Washington; National Comprehensive Center, 2014 [Version 2.2014]."},{"key":"10.1016\/j.dld.2017.05.011_bib0140","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00330-010-1980-7","article-title":"Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up","volume":"21","author":"Parikh","year":"2011","journal-title":"European Radiology"},{"key":"10.1016\/j.dld.2017.05.011_bib0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11307-005-0003-6","article-title":"Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal","volume":"7","author":"Trautmann","year":"2005","journal-title":"Molecular Imaging and Biology"},{"key":"10.1016\/j.dld.2017.05.011_bib0150","first-page":"26","article-title":"Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma","volume":"12","author":"Iagaru","year":"2009","journal-title":"Hellenic Journal of Nuclear Medicine"},{"key":"10.1016\/j.dld.2017.05.011_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2009.04.020","article-title":"Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer","volume":"77","author":"Mistrangelo","year":"2010","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.crad.2011.10.030","article-title":"PET\/CT in anal cancer\u2014is it worth doing?","volume":"67","author":"Wells","year":"2012","journal-title":"Clinical Radiology"},{"key":"10.1016\/j.dld.2017.05.011_bib0165","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/annonc\/mdr599","article-title":"To PET or not to PET? That is the question. Staging in anal cancer","volume":"23","author":"Bhuva","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0170","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s11605-009-0870-2","article-title":"Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging","volume":"13","author":"Otto","year":"2009","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.dld.2017.05.011_bib0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-2001-12860","article-title":"Anal carcinoma: prognostic value of endorectal ultrasound (ERUS). Results of a prospective multicenter study","volume":"33","author":"Giovannini","year":"2001","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2017.05.011_bib0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF00299336","article-title":"Prognostic significance of serum concentration of squamous cell carcinoma antigen in anal epidermoid carcinoma","volume":"8","author":"Goldman","year":"1993","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.dld.2017.05.011_bib0185","series-title":"Radioth\u00e9rapie conformationnelle avec modulation d'intensit\u00e9 dans le cancer anal. Actualisation du rapport de 2006","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2015"},{"key":"10.1016\/j.dld.2017.05.011_bib0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0200","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36Gy elective node irradiation dose in anal cancer","volume":"116","author":"Lepinoy","year":"2015","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0210","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijrobp.2010.02.055","article-title":"High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study)","volume":"80","author":"Hannoun-Levi","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0215","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","article-title":"Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)","volume":"85","author":"Moureau-Zabotto","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0220","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","article-title":"Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study","volume":"85","author":"Deenen","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","volume":"39","author":"Bosset","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0230","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"Suppl","key":"10.1016\/j.dld.2017.05.011_bib0235","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.canrad.2016.07.061","article-title":"Radioth\u00e9rapie des cancer du canal anal","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer Radiotherapie"},{"key":"10.1016\/j.dld.2017.05.011_bib0240","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0245","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0255","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0260","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0265","first-page":"861","article-title":"5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"86","author":"Faivre","year":"1999","journal-title":"Bulletin du Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.11.011","article-title":"Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?","volume":"98","author":"Fraunholz","year":"2011","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0275","first-page":"1634","article-title":"Management of anal cancer in the HIV-positive population","volume":"19","author":"Kauh","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.dld.2017.05.011_bib0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0360-3016(98)00528-8","article-title":"The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer","volume":"44","author":"Hoffman","year":"1999","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2017.05.011_bib0285","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ctrv.2011.02.003","article-title":"Chemotherapy\/chemoradiation in anal cancer: a systematic review","volume":"37","author":"Lim","year":"2011","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.dld.2017.05.011_bib0290","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. NCCN Clinical Practice Guidelines in Oncology 2014."},{"key":"10.1016\/j.dld.2017.05.011_bib0295","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","article-title":"Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial","volume":"92","author":"Hainsworth","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2017.05.011_bib0300","first-page":"4637","article-title":"Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy","volume":"31","author":"Abbas","year":"2011","journal-title":"Anticancer Research"},{"key":"10.1016\/j.dld.2017.05.011_bib0305","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00384-008-0467-3","article-title":"Activity of paclitaxel in metastatic squamous anal carcinoma","volume":"23","author":"Alcindor","year":"2008","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.dld.2017.05.011_bib0310","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1245\/s10434-012-2485-1","article-title":"Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence","volume":"19","author":"Lefevre","year":"2012","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0315","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10350-008-9361-x","article-title":"Abdominoperineal resection for anal cancer","volume":"51","author":"Mariani","year":"2008","journal-title":"Diseases of the Colon and Rectum"},{"key":"10.1016\/j.dld.2017.05.011_bib0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-7697(08)74312-6","article-title":"R\u00e9section R0, seul facteur pronostique dans les amputations abdominop\u00e9rin\u00e9ales de rattrapage des cancers du canal anal (s\u00e9rie cons\u00e9cutive de 95 patients)","volume":"145","author":"Rouquie","year":"2008","journal-title":"Journal de Chirurgie (Paris)"},{"key":"10.1016\/j.dld.2017.05.011_bib0325","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1072-7515(97)00094-X","article-title":"Anal canal and perianal epidermoid cancers","volume":"185","author":"Fuchshuber","year":"1997","journal-title":"Journal of the American College of Surgeons"},{"key":"10.1016\/j.dld.2017.05.011_bib0330","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/DCR.0b013e31819f2a4b","article-title":"Oncologic and functional results after abdominoperineal resection plus pseudocontinent perineal colostomy for epidermoid carcinoma of the anus","volume":"52","author":"Goere","year":"2009","journal-title":"Diseases of the Colon and Rectum"},{"key":"10.1016\/j.dld.2017.05.011_bib0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2011.09.015","article-title":"Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?","volume":"102","author":"Zilli","year":"2012","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0340","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"Suppl. 5","key":"10.1016\/j.dld.2017.05.011_bib0345","doi-asserted-by":"crossref","first-page":"v87","DOI":"10.1093\/annonc\/mdq171","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Glynne-Jones","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2017.05.011_bib0350","series-title":"Common terminology criteria for adverse events (CTCAE)","author":"Anon","year":"2010"},{"key":"10.1016\/j.dld.2017.05.011_bib0355","series-title":"Cooperative group common toxicity criteria","author":"Anon","year":"2015"},{"key":"10.1016\/j.dld.2017.05.011_bib0360","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/crad.2002.0933","article-title":"Recurrent or residual pelvic bowel cancer: accuracy of MRI local extent before salvage surgery","volume":"57","author":"Robinson","year":"2002","journal-title":"Clinical Radiology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817308885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817308885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T10:51:00Z","timestamp":1535799060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817308885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1590865817308885"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.05.011","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}